Navigation Links
Jesper Bramming, former A.P. Moller Executive, Joins the CMC Biologics Executive Management Team as Chief Financial Officer
Date:1/7/2014

COPENHAGEN, Denmark and SEATTLE, Jan. 7, 2014 /PRNewswire/ -- CMC Biologics, a leading biopharmaceutical process development and biopharmaceutical manufacturing organization, announced today that it has appointed Jesper Bramming as Chief Financial Officer (CFO) of its global operations.

(Logo: http://photos.prnewswire.com/prnh/20110502/SF93356LOGO)

Jesper Bramming brings more than 25 years of financial and management experience to CMC Biologics' Executive Management Team, including 9 years as CFO at financial service provider Nets Holding and in two subsidiaries in A. P. Moller – Maersk Group: Maersk Oil & Gas and Svitzer.

Mr. Bramming has previously held international management positions as an equity portfolio manager and financial analyst at A. P. Moller Maersk and within the banking industry. He holds a Master of Economics from the University of Copenhagen and has completed executive education programs at Columbia University, including the Columbia Senior Executive Program.

"We're very pleased to welcome Jesper to our global executive team managing financial operations in both Copenhagen and North American. The breadth of his international finance and financial services expertise is impressive, and we expect him to play a key role in preparing CMC Biologics for its next phase of success," said Claes Glassell, Chief Executive Officer of CMC Biologics.

"CMC Biologics has outstanding process development and manufacturing expertise to serve sophisticated clinical and commercial biopharmaceutical markets," said Jesper Bramming. "I am excited to join the company as it embarks on a new level of growth and I look forward to contributing to the team's execution of its development plan."

About CMC Biologics
CMC Biologics is committed to delivering world class biopharmaceutical process development and manufacturing services, specializing in custom services for scale up and cGMP manufacture of protein-based therapeutics for preclinical, clinical trials, and commercial production. The Company's fully integrated services includes cell line development using its proprietary CHEF1® system, process and formulation development, and comprehensive analytical testing. CMC Biologics has fully segregated microbial fermentation and mammalian cell culture suites and offers stirred tank and perfusion production processes. To learn more, visit www.cmcbiologics.com.

Media Contacts:
Stacie D. Byars
CMC Biologics Global Marketing
sbyars@cmcbio.com
+1 (206) 660-2588


'/>"/>
SOURCE CMC Biologics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cargill’s Dielectric Transformer Oil Made from Natural Esters Wins Presidential Green Chemistry Award
2. Everest Group Recognizes TCS as a Global Leader and Star Performer in Life Sciences IT Outsourcing
3. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
4. McCord Research Hires Former University of Iowa Researcher
5. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
6. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
7. Former COO and CSO of IDEXX Laboratories, Inc. Joins Board of Directors for Vet-Stem, Inc.
8. MEI Pharma Adds Former YM BioSciences CEO Nick Glover To Board Of Directors
9. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
10. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
11. Utah, There is No Better Place U.S. Chamber of Commerce Ranks Utah as the Top Performer in the Nation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... 8, 2016 Oxford ... erweitert seine Palette an anpassbaren SureSeq™ NGS-Panels mit ... Panels, das ein schnelles und kostengünstiges Studium der ... bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, ... einzigen kleinen Panel und ermöglicht eine individuelle Anpassung ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... bioprocess media products engineered to radically streamline culture processes, minimize processing time, ...
(Date:12/8/2016)... Dec. 8, 2016 Soligenix, Inc. (OTCQB: SNGX) ... on developing and commercializing products to treat rare diseases ... that it will be hosting an Investor Webcast Event ... the origins of innate defense regulators (IDRs) as a ... oral mucositis and the recently announced and published Phase ...
Breaking Biology Technology:
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... Valencell , the leading innovator in performance biometric ... consecutive year of triple digit growth for its PerformTek ... 360 percent increase in companies who have acquired Valencell ... sales of its wrist and ear Benchmark™ sensor systems, ... hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
Breaking Biology News(10 mins):